Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Apr 08, 2021 12:03pm
73 Views
Post# 32956975

RE:RE:RE:RE:So far so good

RE:RE:RE:RE:So far so good Thera should hire Dr. Shah to do promo stuff. True or not, we don't care, the important thing is that people talk about the company... (irony here)


Wino115 wrote: I noticed that too.  He listed most of the ones that THTX has also spoken about, but as we know some of those only have one third or so of patients where it overexpresses.  Also, he made it seem like it was a first line approach.  Maybe we'll get there, but we also know that the more severe the cancer metastices, the more sortilin is expressed so it may not be the case.  It's more specialized than what he seemed to be saying in the TV segment.

jfm1330 wrote: Cannot believe they would select a patient without knowing his cancer has overexpression of sortilin. That being said, what Dr. Shah is saying, that it can be used on any solid tumor is scary, because it's not the case. The key of the whole thing is sortilin overexpression. Without that, it will not work as planned.


Wino115 wrote: This is the first time we've heard Prostate Cancer... I'm not sure what level of Sortilin is expressed for that.  Or is that what they've put under the more generic "gynecological" cancers?  Hope it works, but not the primary kind of tumor we're looking for. 


 

 




<< Previous
Bullboard Posts
Next >>